

Yoichiro Yoshida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/757806/publications.pdf>

Version: 2024-02-01

64
papers

1,645
citations

516215

16
h-index

301761

39
g-index

65
all docs

65
docs citations

65
times ranked

2646
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. <i>Cancer Treatment Reviews</i> , 2003, 29, 541-549.	3.4	554
2	P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. <i>Cancer Research</i> , 2003, 63, 3729-34.	0.4	150
3	Cisplatin Resistance and Transcription Factors. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2005, 5, 15-27.	7.0	101
4	Enhanced Expression of the Human Vacuolar H ⁺ -ATPase c subunit Gene (ATP6L) in Response to Anticancer Agents. <i>Journal of Biological Chemistry</i> , 2002, 277, 36534-36543.	1.6	76
5	Impact of perioperative probiotic treatment for surgical site infections in patients with colorectal cancer. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 966-972.	0.8	60
6	Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA. <i>Biochemical and Biophysical Research Communications</i> , 2002, 295, 945-951.	1.0	58
7	Vacuolar H ⁺ -ATPase: functional mechanisms and potential as a target for cancer chemotherapy. <i>Anti-Cancer Drugs</i> , 2002, 13, 237-243.	0.7	49
8	A Study of the Efficacy of Antibacterial Sutures for Surgical Site Infection: A Retrospective Controlled Trial. <i>International Surgery</i> , 2013, 98, 129-132.	0.0	43
9	Low pH enhances Sp1 DNA binding activity and interaction with TBP. <i>Nucleic Acids Research</i> , 2003, 31, 4523-4530.	6.5	35
10	ZNF143 activates gene expression in response to DNA damage and binds to cisplatin-modified DNA. <i>International Journal of Cancer</i> , 2004, 111, 900-909.	2.3	35
11	Binding of RNA to p53 regulates its oligomerization and DNA-binding activity. <i>Oncogene</i> , 2004, 23, 4371-4379.	2.6	34
12	Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX. <i>Cancer Science</i> , 2011, 102, 578-582.	1.7	28
13	Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19836-19850.	1.8	23
14	Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients. <i>International Journal of Clinical Oncology</i> , 2015, 20, 332-337.	1.0	23
15	Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1 β and islet cellular death. <i>Scientific Reports</i> , 2020, 10, 17920.	1.6	23
16	Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 111-117.	1.0	21
17	Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study). <i>Anticancer Research</i> , 2017, 37, 3941-3946.	0.5	18
18	Triclosan sutures for surgical site infection in colorectal cancer. <i>Journal of Surgical Research</i> , 2016, 206, 16-21.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?. Supportive Care in Cancer, 2015, 23, 1623-1627.	1.0	15
20	Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs. Anticancer Research, 2020, 40, 4655-4661.	0.5	15
21	A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab. Case Reports in Oncology, 2014, 7, 426-434.	0.3	14
22	The Relationship Between Evaluation Methods for Chemotherapy-Induced Peripheral Neuropathy. Scientific Reports, 2019, 9, 20361.	1.6	14
23	Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01). World Journal of Surgical Oncology, 2013, 11, 39.	0.8	12
24	Safety and effectiveness of high ligation of the inferior mesenteric artery for cancer of the descending colon under indocyanine green fluorescence imaging: a pilot study. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1696-1702.	1.3	12
25	5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method. Anticancer Research, 2015, 35, 4881-7.	0.5	12
26	Structural and functional characterization of two human V-ATPase subunit gene promoters. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2003, 1628, 97-104.	2.4	11
27	Early Start of Chemotherapy after Resection of Primary Colon Cancer with Synchronous Multiple Liver Metastases:A Case Report. Case Reports in Oncology, 2011, 4, 250-254.	0.3	11
28	Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin. Scientific Reports, 2019, 9, 1819.	1.6	11
29	The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab. Anticancer Research, 2021, 41, 3131-3137.	0.5	11
30	Dexamethasone as a Means Not Only for Controlling Vascular Pain Caused by the Administration of Oxaliplatin Via the Peripheral Vein But Also for Controlling Oxaliplatin-Induced Hypersensitivity Reactions. British Journal of Medicine and Medical Research, 2012, 2, 132-141.	0.2	11
31	Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy. SpringerPlus, 2015, 4, 822.	1.2	10
32	Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. Anticancer Research, 2018, 38, 4367-4373.	0.5	10
33	Multiple Ectopic Hepatocellular Carcinomas Arising in the Abdominal Cavity. Case Reports in Gastroenterology, 2012, 6, 629-634.	0.3	9
34	Transanal TME: new standard or fad?. Journal of the Anus, Rectum and Colon, 2019, 3, 1-9.	0.4	8
35	A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial. Drug Design, Development and Therapy, 2015, 9, 6067.	2.0	7
36	Avoiding urethral and rectal injury during transperineal abdominoperineal resection in male patients with anorectal cancer. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 4679-4682.	1.3	7

#	ARTICLE	IF	CITATIONS
37	Effects of the publication of Clinical Guidelines for the Management of Chemotherapy-Induced Peripheral Neuropathy on the Administration Preferences of Oncology Specialists: Japanese Association of Supportive Care in Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 897-902.	0.6	7
38	Acute chemotherapy-induced peripheral neuropathy due to oxaliplatin administration without cold stimulation. <i>Supportive Care in Cancer</i> , 2020, 28, 5405-5410.	1.0	7
39	Adoptive Chemoimmunotherapy Using Activated $\hat{\pm}\hat{1}^2$ T Cells for Stage IV Colorectal Cancer. <i>Anticancer Research</i> , 2016, 36, 3741-6.	0.5	7
40	Thioredoxin2 enhances the damaged DNA binding activity of mtTFA through direct interaction. <i>International Journal of Oncology</i> , 2009, 35, 1435-40.	1.4	6
41	Early Start of Chemotherapy after Resection of Brain Metastasis from Colon Cancer with Synchronous Multiple Liver Metastases. <i>Case Reports in Oncology</i> , 2012, 5, 290-295.	0.3	6
42	Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 117-121.	0.3	6
43	Endoscopic mucosal incision for successful treatment of submucosal abscess extending the full length of the esophagus due to fish bone: report of a case. <i>Esophagus</i> , 2015, 12, 199-202.	1.0	6
44	Objective evaluation of oxaliplatin-induced vascular pain secondary to peripheral vein administration. <i>SpringerPlus</i> , 2016, 5, 1872.	1.2	6
45	Mutant <i>KRAS</i> Promotes NKG2D ⁺ T Cell Infiltration and CD155 Dependent Immune Evasion. <i>Anticancer Research</i> , 2020, 40, 4663-4674.	0.5	6
46	Comparison of intra-individual coefficients of variation on the paired sampling data when inter-individual variations are different between measures. <i>BMC Research Notes</i> , 2016, 9, 115.	0.6	5
47	Difference in Neutropenia due to Administration Schedule of TAS-102. <i>Case Reports in Oncology</i> , 2017, 10, 226-229.	0.3	4
48	A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study). <i>Journal of the Anus, Rectum and Colon</i> , 2019, 3, 136-141.	0.4	4
49	A case of carbon dioxide embolism during the transperineal approach in total pelvic exenteration for advanced anorectal cancer. <i>Asian Journal of Endoscopic Surgery</i> , 2021, 14, 97-101.	0.4	4
50	Intraoperative pressure monitoring of the lower leg for preventing compression-related complications associated with the lithotomy position. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 5873-5881.	1.3	4
51	New Roles of Mitochondrial Transcription Factor A in Cancer. , 2012, 01, .		3
52	Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study). <i>Scientific Reports</i> , 2019, 9, 16568.	1.6	2
53	5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine. <i>Scientific Reports</i> , 2020, 10, 2711.	1.6	2
54	Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated $\hat{\pm}\hat{1}^2$ T-cells. <i>Anticancer Research</i> , 2017, 37, 3933-3939.	0.5	2

#	ARTICLE	IF	CITATIONS
55	A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study. <i>Journal of the Anus, Rectum and Colon</i> , 2022, 6, 52-57.	0.4	2
56	Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer. <i>Cancer Medicine</i> , 2022, , .	1.3	2
57	Phase II study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02). <i>Annals of Gastroenterological Surgery</i> , 2017, 1, 219-225.	1.2	1
58	Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 13263.	1.6	1
59	Port Free Chemotherapy for Recurrent or Metastatic Colorectal Cancer. Is Port Really Necessary?. <i>Journal of Cancer Science & Therapy</i> , 2012, 04, .	1.7	1
60	A Case of Jejunal Carcinoid Tumor Detected by Huge Nodal Metastasis. <i>Japanese Journal of Gastroenterological Surgery</i> , 2009, 42, 566-570.	0.0	1
61	A Successfully Resected Case of Recurrent Lung and Liver Metastases of Rectal Cancer Treated with XELIRI + Bevacizumab Therapy. <i>Case Reports in Oncology</i> , 2013, 6, 143-147.	0.3	0
62	A Case of Perihilar Cholangiocarcinoma Occurring 49 Years after Surgery for Congenital Biliary Duct Dilatation and 28 Years after Pancreaticoduodenectomy for Pancreatic Duct Stones. <i>Japanese Journal of Gastroenterological Surgery</i> , 2020, 53, 710-717.	0.0	0
63	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	0.6	0
64	Onset of Arterial and Venous Thrombosis and Safety of Antithrombic Therapy in Patients with Gastrointestinal Cancer. <i>gulf journal of oncology, The</i> , 2020, 1, 13-18.	0.2	0